Obstetrics & Gynecology, Female Pelvic Medicine and Reconstructive Surgery · Dallas, TX
NPI
1225053622
Since 2006
Specialty
Obstetrics & Gynecology, Female Pelvic Medicine and Reconstructive Surgery
Code 207VF0040X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
4501 Swiss Ave
Dallas, TX, 75204
Phone (214) 820-8700
Groups this clinician bills Medicare through
Medicare paid, 2024
$561K
27,014 services
Medicare patients, 2024
984
Average age 75
Drug cost, 2024
$581K
3,924 prescriptions
Company payments, 2025
$540
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael E Carley was code J0585 (injection, onabotulinumtoxina, 1 unit), 23,175 times for 91 patients. In total Michael E Carley billed 27,014 services in 65 codes, and Medicare paid $561K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 23,175 | 91 | $4.94 | $115K |
| 99213 Office E&M - Established | Office | 492 | 385 | $65.01 | $32K |
| 81003 Clinical Chemistry | Office | 389 | 280 | $2.20 | $856 |
| 51798 Ultrasound - Nonspecific | Office | 320 | 307 | $8.50 | $2,719 |
| 99214 Office E&M - Established | Office | 317 | 272 | $89.81 | $28K |
| 99204 Office E&M - New | Office | 317 | 317 | $111.15 | $35K |
| 51792 Electrical Nerve Conductivity | Office | 258 | 258 | $203.86 | $53K |
| 99212 Office E&M - Established | Office | 227 | 206 | $35.72 | $8,109 |
| 81002 Clinical Chemistry | Office | 200 | 163 | $3.40 | $680 |
| 52287 Cystourethroscopy | Office | 169 | 93 | $281.55 | $48K |
| 52000 Cystourethroscopy | Office | 96 | 96 | $178.19 | $17K |
| 51784 Neurologic | Office | 91 | 91 | $25.18 | $2,292 |
| 57265 Other Organ Systems | Facility | 90 | 90 | $517.49 | $47K |
| 51797 Other Organ Systems | Office | 88 | 88 | $144.65 | $13K |
| 51729 Other Organ Systems | Office | 86 | 86 | $279.25 | $24K |
By year: 2022 $538K for 21,277 services; 2023 $545K for 22,318 services; 2024 $561K for 27,014 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 389 | 280 | $2.20 | $856 |
| 81002 Clinical Chemistry | 200 | 163 | $3.40 | $680 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael E Carley prescribed most often to Medicare patients was Methenamine Hippurate, with 626 prescriptions and refills. In total Michael E Carley wrote 3,924 Medicare prescriptions that cost $581K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methenamine Hippurate Generic | 626 | 1,127 | 174 | $51K |
| Trospium Chloride Generic | 519 | 1,236 | 214 | $27K |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 490 | 490 | 322 | $5,693 |
| Gemtesa Vibegron | 360 | 665 | 103 | $319K |
| Estradiol Generic | 274 | 976 | 202 | $19K |
| Cephalexin Generic | 195 | 348 | 124 | $1,723 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 185 | 185 | 148 | $1,282 |
| Solifenacin Succinate Generic | 178 | 377 | 62 | $7,206 |
| Myrbetriq Mirabegron | 127 | 217 | 51 | $96K |
| Tramadol Hcl Generic | 97 | 97 | 93 | $235 |
| Fluconazole Generic | 54 | 54 | 46 | $282 |
| Cefdinir Generic | 45 | 47 | 42 | $681 |
| Gabapentin Generic | 43 | 47 | 26 | $162 |
| Bethanechol Chloride Generic | 42 | 52 | Under 11 | $738 |
| Clobetasol Propionate Generic | 41 | 54 | 27 | $1,101 |
Brand drugs: - claims; generic drugs: 3,230 claims; opioid claims: 126.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael E Carley $540 ($540 in general payments such as food, travel and fees) from 7 companies. The largest payer was Abbvie Inc. with $241.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.